Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
January 05, 2022 07:00 ET
|
Imara, Inc.
BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects...
New gene therapy could provide cure for sickle cell disease, according to UAB study
December 17, 2021 10:36 ET
|
University of Alabama at Birmingham
BIRMINGHAM, Ala., Dec. 17, 2021 (GLOBE NEWSWIRE) -- New research from University of Alabama at Birmingham, published in the New England Journal of Medicine, suggests a gene therapy called...
Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021
December 14, 2021 07:00 ET
|
Imara, Inc.
Oral presentation provides first look at new program, IMR-261, a novel, oral, clinic-ready nuclear factor erythroid 2-related factor 2 (Nrf2) activator SCD Townes mouse model demonstrates IMR-261...
Protecting the brain in sickle cell anemia: the value of beginning early in life
December 06, 2021 10:00 ET
|
Experimental Biology and Medicine
WASHINGTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- A recently published article in Experimental Biology and Medicine (Volume 246, Issue 23, December, 2021) highlights the importance of early-in-life...
Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease
November 22, 2021 07:00 ET
|
Imara, Inc.
Primary endpoint to be changed to annualized rate of VOCs following written U.S. Food and Drug Administration recommendation No change to conduct or size of trial planned; Ardent trial remains on...
Imara Reports Third Quarter 2021 Financial Results and Business Highlights
November 09, 2021 07:00 ET
|
Imara, Inc.
Interim analysis data for Phase 2b clinical trials of tovinontrine (IMR-687) in patients with beta-thalassemia and sickle cell disease expected in fourth quarter of 2021 Introduction of pipeline...
Imara to Webcast Conference Call of Third Quarter 2021 Financial Results and Business Highlights
November 04, 2021 16:01 ET
|
Imara, Inc.
BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara to Participate in Upcoming Investor Conferences
September 15, 2021 07:00 ET
|
Imara, Inc.
BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara to Present at Upcoming Investor Conferences
September 03, 2021 07:00 ET
|
Imara, Inc.
BOSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Reports Second Quarter 2021 Financial Results and Business Highlights
August 06, 2021 07:00 ET
|
Imara, Inc.
Accelerated enrollment in Phase 2b trials in sickle cell disease and beta-thalassemia; interim analyses expected in fourth quarter of 2021 Positive IMR-687 data in sickle cell disease presented at...